Behzad Doratotaj

Behzad Doratotaj practices at MedStar Montgomery Medical Center in Olney, Maryland, part of MedStar Health.

Behzad Doratotaj's NPI, 1063675890, was assigned on July 2, 2008. Behzad Doratotaj holds Maryland license D87116.

Behzad Doratotaj's primary practice is MedStar Montgomery Medical Center, at 18101 Prince Philip Drive, Olney, MD 20832 in Montgomery County. The practice phone is (301) 774-8771.

Behzad Doratotaj's primary practice is MedStar Montgomery Medical Center in Olney, Maryland, part of MedStar Health. Behzad Doratotaj is also affiliated with MedStar Georgetown University Hospital. The medical group on file is MedStar Medical Group. Dmand AI also links Behzad Doratotaj to 1 more hospital and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Behzad Doratotaj practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Behzad Doratotaj's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Behzad Doratotaj's licenses on file in 3 states: Maryland, New York and Pennsylvania.

CMS data shows 1,115 Medicare services from Behzad Doratotaj across 8 procedure codes in 2024, for 366 Medicare patients. Medicare paid $157,929 for them.

CMS counts 366 Medicare patients who saw Behzad Doratotaj in 2024. The largest group is 75 to 84, with 148 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 1.73, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Behzad Doratotaj's median patient age at 70, with 69% women.

In 2024, Behzad Doratotaj wrote 452 Medicare Part D claims for 97 patients. 72% of them were for generic drugs. CMS names the drug for 332 of them, across 15 drugs with 11 or more claims each, at $861,697 in total drug cost. In 2023, CMS named 192 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 82 out of 100 for Behzad Doratotaj for performance year 2024, reported as part of a group. Behzad Doratotaj accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Behzad Doratotaj as offering telehealth.

Dmand AI links 2 papers to Behzad Doratotaj, published from 2017 to 2018. Behzad Doratotaj has published most often in BMJ Case Rep. Behzad Doratotaj's most frequent co-authors are Soren Gandhi, MD and Ahmed Jamal Nadeem, DO.

CMS Open Payments shows 31 general payments to Behzad Doratotaj from 18 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 63% of the total. Eli Lilly and Company paid the most, $291.